Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Back to dashboard
Company Information
About this company
Key people
H. Stewart Parker
Independent Chairman of the Board
Margaret A. Horn
Independent Director
Alexander D. Macrae
President, Chief Executive Officer, Director
Nikunj Jain
Interim Chief Financial Officer, Principal Accounting Officer
Gregory Davis
Head of Research & Technology
Nathalie Dubois-Stringfellow
Chief Development Officer
Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Courtney Beers
Independent Director
Robert F. Carey
Independent Director
Kenneth J. Hillan
Independent Director
Click to see more
Key facts
- Shares in issue414.29m
- EPICSGMOQ
- ISINUS8006771062
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$60.20m
- Employees142
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.